Adam JohnsonFounder and Author, Bullseye Brief
About Adam Johnson
Adam Johnson is founder and author of Bullseye Brief, an investment newsletter that presents thematic and actionable ideas twice a month. He anchored several business programs at Bloomberg Television over five years, interviewing CEOs, heads of state and prominent investors. His daily video investment blog, Insight and Action, was sponsored by a major U.S. lender.
Previously he managed global risk assets for ING Furman Selz and Louis Dreyfus, trading oil futures, listed equities and equity options.
Adam began his career at Merrill Lynch with a degree in economics from Princeton.
Follow him on Twitter at @AJInsight.
Join InvestorPlace Insights — FREE!
Get actionable advice from our top experts, including the hottest stocks to buy & sell, 401k and retirement tips, market analysis and more!
Zynerba is working to bring its marijuana-based medications through trials and investors seem to be rewarding ZYNE stock.
Lithium is unquestionably a game changer, and these three Lithium stocks are a good way to join the party for cheap.
Alphabet (GOOGL) is the most explosive innovator in global technology. Yet somehow, GOOGL stock still boasts an attractive price. Don't wait.
ZYNE stock has a couple of promising therapies in trials that could make 2017 a great year for Zynerba stockholders.
The Yahoo hack is unsettling, but Verizon stock is better off with YHOO under the fold regardless. It just needs to save a little face.